Study of TAK-505 for adults with solid tumors
Part of Cancer clinical trials.
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor that has spread or cannot be removed with surgery, and standard treatments have failed or are not an option.
- You need to provide a tumor sample (either from a past biopsy or a new one).
- You should be able to do daily activities with little to no help (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on scans.
- Your blood cell counts, liver, and kidney function must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, TAK-188, for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if it can help shrink or slow the growth of the cancer.
This Phase 1 trial tests how safe TRE-515 is, what dose can be used, and how the drug moves through the body, including using PET scans. It’s for adults with advanced solid cancers that have stopped responding to standard treatment.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
This is an early-stage study testing a new drug called GTB-5550 in people with advanced cancers that have spread. The study aims to find the right dose and see if the drug helps shrink tumors.
Hear when a new Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.